L
Lyndell L Lim
Researcher at University of Melbourne
Publications - 159
Citations - 4974
Lyndell L Lim is an academic researcher from University of Melbourne. The author has contributed to research in topics: Uveitis & Medicine. The author has an hindex of 27, co-authored 139 publications receiving 3963 citations. Previous affiliations of Lyndell L Lim include Royal Melbourne Hospital & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia
Sophie Rogers,Rachel McIntosh,Ning Cheung,Lyndell L Lim,Jie Jin Wang,Jie Jin Wang,Paul Mitchell,Jonathan W. Kowalski,Hiep Nguyen,Tien Yin Wong,Tien Yin Wong +10 more
TL;DR: The study provides summary data on the prevalence of RVO and suggests that approximately 16 million people may have this condition and research on preventive and treatment strategies for this sight-threatening eye disease is needed.
Journal ArticleDOI
Natural History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review
Rachel McIntosh,Sophie Rogers,Lyndell L Lim,Ning Cheung,Jie Jin Wang,Jie Jin Wang,Paul Mitchell,Jonathan W. Kowalski,Hiep Nguyen,Tien Yin Wong,Tien Yin Wong +10 more
TL;DR: Visual acuity generally improved in eyes with BRVO without intervention, although clinically significant improvement beyond 20/40 was uncommon, and the best available evidence from the literature indicated this was uncommon.
Journal ArticleDOI
Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.
TL;DR: Etanercept therapy is associated with a significantly greater number of reported uveitis cases in comparison with infliximab and adalimumab in 2 medication side effect registries, which are consistent with previous studies and suggest that this relationship is drug specific and not related to TNF inhibitors as a whole.
Journal ArticleDOI
A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.
Mark C Gillies,Lyndell L Lim,Anna Campain,Godfrey J. Quin,Wedad Salem,Ji Li,Stephanie Goodwin,Christine Aroney,Ian L. McAllister,Samantha Fraser-Bell +9 more
TL;DR: In this article, the authors reported the 12-month results of the first head-to-head comparison of a dexamethasone implant (Ozurdex; Allergan, Inc., Irvine, CA) versus bevacizumab (Avastin; Genentech, South San Francisco, CA).
Journal ArticleDOI
Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
Yuichiro Ogura,Johann Roider,Jean-François Korobelnik,Jean-François Korobelnik,Frank G. Holz,Christian Simader,Ursula Schmidt-Erfurth,Robert Vitti,Alyson J. Berliner,Florian Hiemeyer,Brigitte Stemper,Brigitte Stemper,Oliver Zeitz,Rupert Sandbrink,Rupert Sandbrink,Mark C Gillies,Jennifer Arnold,Ian L. McAllister,Simon D.M. Chen,Paul Mitchell,Lyndell L Lim,Ulrich Schoenherr,Siegfried G. Priglinger,F. Devin,Michel Paques,Gabriel Quentel,Michel Weber,Catherine Creuzot-Garcher,Frank G. Holz,Sabine Aisenbrey,Lutz L. Hansen,Peter Wiedemann,Chris P. Lohmann,Norbert Pfeiffer,Stefan Dithmar,Dirk Sandner,Bernd Kirchhof,Helmut G. Sachs,Salvatore Grisanti,Nicolas Feltgen,Karl Heinz Emmerich,Lars-Olaf Hattenbach,Peter Walter,Katrin Engelmann,Norbert Bornfeld,Andreea Gamulescu,Gisbert Richard,Berthold Seitz,Stefan Mennel,D. Pauleikhoff,Frank Koch,András Papp,József Ferenc Györy,Ágnes Kerényi,András Seres,András Berta,Lajos Szalczer,Francesco Boscia,Alfonso Giovannini,Ugo Menchini,Frederico Ricci,Monica Varanno,Francesco Viola,Rosangela Lattanzio,Alfredo Reibaldi,Frederico Grignolo,Miki Honda,Hiroko Terasaki,Nagahisa Yoshimura,Mitsuko Yuzawa,Motohiro Kamei,Ilze Zarinova,Guna Laganovska,Ranjana Mathur,Caroline Chee,Dong-Heun Nam,Se Joon Woo,Young-Hee Yoon,Won Ki Lee,Hyeong Gon Yu,Hyoung-Jun Koh +80 more
TL;DR: The visual and anatomic improvements seen after fixed, monthly dosing at week 24 were largely maintained when treatment intervals were extended, and patients with macular edema following CRVO benefited from early treatment with intravitreal aflibercept.